Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer
Sera Prognostics (NASDAQ:SERA) has appointed Dr. Tiffany Inglis as Chief Medical Officer. Dr. Inglis, who previously held clinical leadership positions at Elevance Health and Carelon Health, brings extensive experience in women's and children's health programs.
As a former practicing OBGYN with over a decade of experience, Dr. Inglis will lead Sera's clinical operations to advance the company's position in women's health diagnostics, particularly focusing on the PreTRM® Test. Her appointment comes at a crucial time as the company prepares for the publication of the PRIME study and launches pilots with state Medicaid programs.
Dr. Inglis received her medical degree from the Medical College of Ohio in 2002 and completed her Obstetrics and Gynecology residency at Riverside Methodist Hospital in 2006. Her expertise includes implementing cost-effective solutions for improving maternal and neonatal outcomes.
Sera Prognostics (NASDAQ:SERA) ha nominato Dott.ssa Tiffany Inglis come Chief Medical Officer. La Dott.ssa Inglis, che in passato ha ricoperto ruoli di leadership clinica presso Elevance Health e Carelon Health, porta una vasta esperienza nei programmi di salute femminile e pediatrica.
In quanto ex ostetrica-ginecologa praticante con oltre dieci anni di esperienza, la Dott.ssa Inglis guiderà le operazioni cliniche di Sera per rafforzare la posizione dell’azienda nelle diagnostiche della salute della donna, con particolare attenzione al test PreTRM®. La sua nomina arriva in un momento cruciale, mentre l’azienda si prepara alla pubblicazione dello studio PRIME e al lancio di progetti pilota con i programmi Medicaid statali.
La Dott.ssa Inglis ha conseguito la laurea in medicina presso il Medical College of Ohio nel 2002 e ha completato la residenza in Ostetricia e Ginecologia presso l’Riverside Methodist Hospital nel 2006. La sua esperienza comprende l’implementazione di soluzioni economiche per migliorare gli esiti materni e neonatali.
Sera Prognostics (NASDAQ:SERA) ha designato la Dra. Tiffany Inglis como Chief Medical Officer. La Dra. Inglis, que previamente ocupó puestos de liderazgo clínico en Elevance Health y Carelon Health, aporta una amplia experiencia en programas de salud de mujeres y niños.
Como ex obstetra-ginecóloga en ejercicio con más de una década de experiencia, la Dra. Inglis pilotará las operaciones clínicas de Sera para reforzar la posición de la empresa en diagnósticos de salud femenina, con especial foco en el Test PreTRM®. Su nombramiento llega en un momento clave, cuando la empresa se prepara para la publicación del estudio PRIME y para el lanzamiento de pilotos con programas estatales de Medicaid.
La Dra. Inglis obtuvo su título de médica en el Medical College of Ohio en 2002 y completó su residencia en Obstetricia y Ginecología en Riverside Methodist Hospital en 2006. Su experiencia incluye implementar soluciones rentables para mejorar los resultados maternos y neonatales.
Sera Prognostics(나스닥:SERA)가 Tiffany Inglis 박사를 최고의료책임자(CMO)로 임명했습니다. 과거 Elevance Health와 Carelon Health에서 임상 리더십 직책을 맡았던 Inglis 박사는 여성 및 소아 건강 프로그램에 대한 폭넓은 경험을 가져옵니다.
10년이 넘는 경력을 가진 현직 산부인과 의사로서 Inglis 박사는 Sera의 임상 운영을 주도하여 여성 건강 진단 분야에서 회사의 입지를 강화하고 특히 PreTRM® 테스트에 집중할 것입니다. 이번 임명은 PRIME 연구 결과가 공개되고 주 정부 Medicaid 프로그램과의 파일럿을 시작하는 중요한 시기에 이뤄졌습니다.
Inglis 박사는 2002년 오하이오 의과대학에서 의학 학위를 받았고 2006년 Riverside Methodist Hospital에서 산부인과 레지던시를 마쳤습니다. 그녀의 전문 분야에는 산모 및 신생아 결과를 개선하기 위한 비용 효율적 솔루션의 구현이 포함됩니다.
Sera Prognostics (NYSE: SERA) a nommé Dr Tiffany Inglis comme Chief Medical Officer. La Dre Inglis, qui occupait auparavant des postes de direction clinique chez Elevance Health et Carelon Health, apporte une vaste expérience dans les programmes de santé des femmes et des enfants.
Ancienne obstétricienne-gynécologue praticante forte de plus d’une décennie d’expérience, la Dre Inglis dirigera les opérations cliniques de Sera afin de renforcer la position de l’entreprise dans le domaine des diagnostics de santé féminine, en mettant l’accent sur le test PreTRM®. Sa nomination intervient à un moment crucial, alors que l’entreprise se prépare à la publication de l’étude PRIME et au lancement de pilotes avec les programmes Medicaid des états.
La Dre Inglis a obtenu son diplôme de médecine à la Medical College of Ohio en 2002 et a terminé sa residency en obstétrique et gynécologie au Riverside Methodist Hospital en 2006. Son expertise comprend la mise en œuvre de solutions rentables pour améliorer les résultats maternels et néonatals.
Sera Prognostics (NASDAQ:SERA) hat Dr. Tiffany Inglis zur Chief Medical Officer ernannt. Dr. Inglis, die zuvor Führungspositionen in der Klinik bei Elevance Health und Carelon Health innehatte, bringt umfangreiche Erfahrungen in Programmen zur Frauengesundheit und Kinderheilkunde mit.
Als ehemalige praktizierende Frauenärztin mit über einem Jahrzehnt Erfahrung wird Dr. Inglis die klinischen Abläufe von Sera leiten, um die Stellung des Unternehmens im Bereich der Diagnostik der Frauengesundheit zu festigen, mit besonderem Fokus auf den PreTRM®-Test. Ihre Ernennung erfolgt zu einem entscheidenden Zeitpunkt, da das Unternehmen die Veröffentlichung der PRIME-Studie vorbereitet und Piloten mit staatlichen Medicaid-Programmen startet.
Dr. Inglis erwarb 2002 ihren medizinischen Abschluss am Medical College of Ohio und schloss 2006 ihre Facharztausbildung in Geburtshilfe und Gynäkologie am Riverside Methodist Hospital ab. Zu ihren Fachgebieten gehört die Umsetzung kosteneffektiver Lösungen zur Verbesserung mütterlicher und neonataler Ergebnisse.
Sera Prognostics (ناسداك:SERA) عينت الدكتورة تيفاني إنجليز كمدير طبي أول. تمتك الدكتورة إنجليز، التي شغلت مناصب قيادية klinية سابقاً في Elevance Health وCarelon Health، خبرة واسعة في برامج صحة النساء والأطفال.
باعتبارها طبيبة توليد وأمراض نساء ممارسة سابقاً مع أكثر من عقد من الخبرة، ستقود الدكتورة إنجليز العمليات السريرية لشركة سيرا لتعزيز موقف الشركة في تشخيصات صحة النساء، مع تركيز خاص على اختبار PreTRM®. تأتي تعيينها في وقت حاسم بينما تستعد الشركة لنشر دراسة PRIME وتطلق تجارب pilots مع برامج Medicaid الحكومية.
حصلت الدكتورة إنجليز على درجة الطب من كلية الطب في أوهايو في 2002 وCompleted إقامتها في تخصص أمراض النساء والولادة في مستشفى Riverside Methodist في 2006. تشمل خبرتها تنفيذ حلول فعالة من حيث التكلفة لتحسين نتائج الأم والجنين.
Sera Prognostics（纳斯达克股票代码:SERA）任命 Tiffany Inglis 博士为首席医疗官。Inglis 博士此前在 Elevance Health 与 Carelon Health 担任临床领导职务，拥有丰富的女性与儿童健康项目经验。
作为一位拥有十余年临床经验的在职产科医生，Inglis 博士将领导 Sera 的临床运营，推动公司在女性健康诊断领域的地位，特别聚焦 PreTRM® 测试。她的任命正值公司为 PRIME 研究的发布做准备，并启动与州级 Medicaid 计划的试点之际。
Inglis 博士于 2002 年在俄亥俄医学院获得医师执照，并于 2006 年在 Riverside Methodist Hospital 完成产科和妇科住院医师培训。她的专长包括为改善孕产妇与新生儿结局而实施具有成本效益的解决方案。
- Appointment of experienced Chief Medical Officer with both clinical and payer network expertise
- Strategic timing with upcoming PRIME study publication and Medicaid program pilots
- Enhanced leadership for commercial strategy and clinical operations
- None.
Dr. Inglis joins Sera following years of clinical leadership positions at Elevance Health and Carelon Health where she focused on member facing programs including women's and children's health, driving initiatives that improved access to quality care while demonstrating meaningful cost-savings. Her expertise in clinical operations will bolster Sera's commercial strategy as the company looks to position its data to drive coverage, support updates to clinical practice guidelines and help ensure the PreTRM® Test is standard of care to benefit babies and families.
"As an OBGYN, Dr. Inglis understands the importance of delivering real-time, actionable information to patients that can achieve healthier outcomes for both mom and baby," said Zhenya Lindgardt, CEO of Sera Prognostics. "The intersection of her clinical expertise and her more recent tenure as Chief Medical Officer and Medical Director across major payer networks makes her the perfect fit for Sera during a pivotal time, as we prepare for publication of the PRIME study and launch pilots with state Medicaid programs with our breakthrough PreTRM Test."
Dr. Inglis received a medical degree from the Medical College of
"I've dedicated my career to improving outcomes for mothers and babies, and I'm thrilled to join Sera to continue this work," said Dr. Inglis. "Sera has an incredible opportunity to transform the maternal and neonatal care landscape to be more proactive, personalized and accessible for women to ultimately make the best decisions about their health. I look forward to collaborating on the organization's leading innovation to drive greater awareness around pre-term birth to deliver meaningful clinical outcomes for women and babies."
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM ®Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2024 March of Dimes Report Card shows that, for the last six consecutive years, more than one in ten infants is born prematurely in
About the PreTRM
®
Test
The PreTRM Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to establishing the Company as a leader in women's health diagnostics; driving coverage, supporting updates to clinical practice guidelines and ensuring the PreTRM® Test is standard of care; publication of the PRIME study; launching pilots with state Medicaid programs; transforming the maternal and neonatal care landscape to be more proactive, personalized and accessible for women; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Contact
Investor Contact
Jennifer Zibuda
Head of Investor Relations
Jzibuda@sera.com
(801) 396-8043
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-names-dr-tiffany-inglis-chief-medical-officer-302571750.html
SOURCE Sera Prognostics, Inc.
FAQ
Who is the new Chief Medical Officer of Sera Prognostics (NASDAQ:SERA)?
What is Dr. Tiffany Inglis's background and experience before joining Sera Prognostics?
What will be Dr. Inglis's main responsibilities at Sera Prognostics?
What upcoming initiatives is Sera Prognostics preparing for?
